Evaluating Baricitinib for Skin Tightening in Systemic Sclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and efficacy of baricitinib, a JAK inhibitor, in treating skin tightening associated with diffuse cutaneous systemic sclerosis (dcSSc). Participants will be randomly assigned to receive either baricitinib or methotrexate, a traditional treatment for this condition. The study aims to assess changes in skin involvement using the modified Rodnan skin score (mRSS) over a specified period. It is an open-label trial conducted at Bangabandhu Sheikh Mujib Medical University in Dhaka, Bangladesh.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Diagnosis of diffuse cutaneous systemic sclerosis, as classified using the 2013 American College of Rheumatology

  2\. Diffuse cutaneous systemic sclerosis as defined by 2001 LeRoy and Medsger 3. Disease duration ≤ 60 months (defined as time from the first non-Raynaud phenomenon manifestation) 4. mRSS score ≥ 10 at baseline

Exclusion Criteria:

Subjects with any of the following characteristics/conditions will not be included in the study:

1. Rheumatic disease other than systemic sclerosis. it is acceptable to include patients with fibromyalgia and scleroderma-associated myopathy
2. Limited cutaneous systemic sclerosis or sine scleroderma at the screening visit
3. Major surgery (including joint surgery) within 8 weeks prior to screening visit
4. Any infected ulcer prior to treatment
5. Subjects with any serious bacterial infection (e.g.,chronic pyelonephritis, osteomyelitis, or bronchiectasis) .
6. Oral corticosteroids \>10 mg/day of prednisone or equivalent.
7. Mycophenolate mofetil \> 2 grams/day prior to baseline
8. Pulmonary disease with FVC ≤ 50% of predicted, or DLCO (uncorrected for hemoglobin) ≤ 40% of predicted
9. Current clinical, radiographic, or laboratory evidence of active TB.
10. Positive for hepatitis B surface antigen at or within 30 days of screening.
11. Positive for hepatitis C antigen at or within 30 days of screening.
12. Current or recent history of uncontrolled clinically significant renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease.
13. Pregnant or breastfeeding female subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in the protocol for the duration of the study and for at least 28 days after discontinuation of study drug.
14. History of any malignancy in the last 5 years
15. History of SSc Renal Crisis within the 6 months prior to baseline.
16. Patients with a history of anaphylaxis to Baricitinib or methotrexate
17. Any of the following lab results at screening:

    * Hemoglobin \<8 g/dl
    * White Blood Cell count \<3.0 x 109/L;
    * Absolute Neutrophil count \<1.2 x 109/L;
    * Platelet count \<100 x 109/L;
    * Absolute Lymphocyte count \<0.75 x 109/L.
    * ALT \> 3 × the upper limit of normal (ULN) of normal at screening
    * Estimated glomerular filtration rate \[GFR\] \<60mL/min/1.73 m2

Where it's running

• Bsmmu
  Dhaka, Bangladesh Recruiting

Study contacts

• Principal investigator: Dr MD. Fahad Hossain, MBBS, MD — Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
• Study coordinator: Dr Md. Fahad Hossain, MBBS, MD
• Email: fhosen14@gmail.com
• Phone: +8801811237435

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

• Can older adults with breast cancer tolerate a dense CMF chemo schedule

  This study tests whether giving a condensed CMF chemotherapy regimen is feasible for people 70 and older with breast cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07768436

• Anti-CD25 antibody to prevent acute GVHD after haploidentical stem cell transplant

  This study tests whether an anti-CD25 antibody can better prevent acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation compared with the usual methotrexate-based approach.

  Recruiting Phase 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07689630

• R-PMDT Regimen for Newly Diagnosed PCNSL

  This study tests the R-PMDT treatment approach in people newly diagnosed with primary CNS lymphoma to see how many respond.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07604987

• Intrathecal methotrexate-loaded tumor-derived vesicles for leptomeningeal lung cancer

  This treatment will try giving methotrexate-loaded tumor-derived vesicles into the spinal fluid to see if it is safe and helps adults with leptomeningeal metastasis from lung cancer who have not responded to standard treatments.

  Recruiting Phase 1/2 Henan Cancer Hospital · Zhengzhou, Henan · NCT07559097

• Baricitinib for persistent low platelets after stem cell transplant

  We’re testing baricitinib to see if it can help people with long-term low platelets after an allogeneic stem cell transplant who didn’t respond to other treatments.

  Recruiting Phase 1/2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07535645

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.